

Maeve Jones-O'Connor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2637801/publications.pdf>

Version: 2024-02-01

19
papers

930
citations

933264

10
h-index

839398

18
g-index

24
all docs

24
docs citations

24
times ranked

1348
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE, 2022, 17, e0265767.	1.1	9
2	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007440.	0.9	16
3	The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. JACC: CardioOncology, 2021, 3, 101-109.	1.7	31
4	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
5	The Intersection of Type 2 Myocardial Infarction and Heart Failure. Journal of the American Heart Association, 2021, 10, e020849.	1.6	2
6	Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. EBioMedicine, 2021, 72, 103593.	2.7	8
7	Preventive Management of Nonobstructive CAD After Coronary CT Angiography in the Emergency Department. JACC: Cardiovascular Imaging, 2020, 13, 437-448.	2.3	20
8	Application of the GRACE, TIMI, and TARRACO Risk Scores in Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2020, 75, 344-345.	1.2	9
9	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine, 2020, 26, 100504.	3.2	44
10	Homeâ€Time After Discharge Among Patients With Type 2 Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e015978.	1.6	7
11	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation, 2020, 141, 2031-2034.	1.6	142
12	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European Heart Journal, 2020, 41, 1733-1743.	1.0	212
13	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. Journal of the American College of Cardiology, 2020, 75, 467-478.	1.2	179
14	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1
15	Sex Differences in Patient Characteristics, Treatment Strategies, and Outcomes for Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 3230-3232.	1.2	10
16	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.4	42
17	Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2005-2007.	1.2	10
18	Misclassification of Myocardial Injury as Myocardial Infarction. JAMA Cardiology, 2019, 4, 460.	3.0	80

#	ARTICLE	IF	CITATIONS
19	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59